Vancouver, British Columbia - January 24, 2012 - Sirona Biochem Corp. (TSX-V: SBM, OTC: SRBCF, Frankfurt: ZSB) (the "Company"), a biotechnology company specializing in carbohydrate chemistry technology, announced today the appointment of Sean Cunliffe to the position of Chief Business Officer and to its Board of Directors. Mr. Cunliffe will be responsible for strategic planning and direction, overseeing operations, program evaluation and selection, expansion, and business development and licensing of Sirona Biochem's programs.
"Sean Cunliffe brings a wealth of biotechnology and pharmaceutical executive experience and has been a key player in negotiating major pharmaceutical partnerships," said Dr. Howard Verrico, President & CEO of Sirona Biochem. "We are thrilled to welcome Sean to Sirona Biochem and know his talent comes at the right time for our company as our programs mature to a partner-ready stage," Dr. Verrico added.
Sirona Boiochem Corp. has granted a total of 2,000,000 stock options pursuant to the company's stock option plan. These options expire in five years, have an exercise price of $0.12 cents per share and are subject to vesting. These options are granted to Sean Cunliffe in connection with his appointment as Chief Business Officer and appointment to the board of directors. These options and the board of director appointment are subject to receipt of all necessary regulatory approvals.
About Sean Cunliffe
Mr. Sean Cunliffe has more than 25 years of pharmaceutical
marketing and sales experience in a wide variety of
therapeutic areas. Most recently, he was Senior Vice
President of Sales and Marketing at Angiotech
Pharmaceuticals. Prior to Angiotech, Mr. Cunliffe served as
Chief Commercial Officer of Neuromed Pharmaceuticals, now
Zalicus Inc. At Neuromed, Mr. Cunliffe negotiated,
from ALZA Corporation, the in-licensing of a once-daily
hydromorphone, now marketed as Exalgo®. He also
negotiated a partnership and research collaboration with
Merck, in what was noted at the time as the largest
pharmaceutical deal in Canadian history. Mr. Cunliffe
has held several leadership roles at Wyeth Pharmaceuticals
in Collegeville, PA, including Vice President of New
Product Marketing where he co-chaired, along with
Discovery, both the Neuroscience and Cardiovascular
leadership teams, Vice President Marketing and Global
Business Manager of Neuroscience and Vice President of
Cardiovascular and Gastrointestinal Marketing. Prior to
Wyeth, he was the Group Director U.S. Marketing,
Gastrointestinal and Anti-Viral Products at Glaxo Wellcome
in Research Triangle Park, NC. Mr. Cunliffe also served for
Glaxo and Astra Pharmaceuticals in a variety of sales and
marketing roles in Canada before moving to the US to work
in both global and US domestic commercial functions. Mr.
Cunliffe received an MBA in Finance from McMaster
University in Hamilton, Ontario and an Honours B.Sc. in
Biology from Queen's University in Kingston, Ontario.
About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company developing
diabetes therapeutics, cancer vaccine antigens,
depigmenting and anti-aging agents for cosmetic use and
biological ingredients. The company utilizes a
proprietary chemistry technique to improve pharmaceutical
properties of carbohydrate-based molecules. For more
information visit .
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, contact:
Julie Jang
Director, Communications
Sirona Biochem Corp.
Phone: 604.282.6065
Email: jjang@sironabiochem.com
---------------
Sirona Biochem cautions you that statements included in
this press release that are not a description of historical
facts may be forward-looking statements. Forward-looking
statements are only predictions based upon current
expectations and involve known and unknown risks and
uncertainties. You are cautioned not to place undue
reliance on these forward-looking statements, which speak
only as of the date of release of the relevant information,
unless explicitly stated otherwise. Actual results,
performance or achievement could differ materially from
those expressed in, or implied by, Sirona Biochem's
forward-looking statements due to the risks and
uncertainties inherent in Sirona Biochem's business
including, without limitation, statements about: the
progress and timing of its clinical trials; difficulties or
delays in development, testing, obtaining regulatory
approval, producing and marketing its products; unexpected
adverse side effects or inadequate therapeutic efficacy of
its products that could delay or prevent product
development or commercialization; the scope and validity of
patent protection for its products; competition from other
pharmaceutical or biotechnology companies; and its ability
to obtain additional financing to support its
operations. Sirona Biochem does not assume any
obligation to update any forward-looking statements except
as required by law.
distribué par | Ce noodl a été diffusé par Sirona Biochem Corp. et initialement mise en ligne sur le site http://www.sironabiochem.com. La version originale est disponible ici. Ce noodl a été distribué par noodls dans son format d'origine et sans modification sur 2012-01-24 15:18:13 PM et restera accessible depuis ce lien permanent. Cette annonce est protégée par les règles du droit d'auteur et toute autre loi applicable, et son propriétaire est seul responsable de sa véracité et de son originalité. |